ATS 2024 Final Program

Click on the session title to view the speakers

345

WEDNESDAY • MAY 22

418 Automated CT Quantification of Changes to the Heart and Pulmonary Artery Post PTE in Patients With CTEPH 419 Image-based Hemodynamic Model of Patient With Microvascular Disease in Chronic Thromboembolic Pulmonary Hypertension 420 Initial Long-term Data From a Phase 3 Open-label Extension Study (ROR-PH-303) Evaluating Ralinepag for the Treatment of Pulmonary Arterial Hypertension (Advance Extension) 421 Quantitative Computed Tomography Analysis of Small Vessel Volume and Density by Age, Sex, and Etiology in PAH 422 Three-dimensional (3D) Right Ventricular Surface Strain Computed From 3D Echocardiography Correlates With RVEF and Reveals Differences in Deformation Based on Severity of Pulmonary Arterial Hypertension Symptoms 423 Prognostic Value of Follow-up Hemodynamics After Initial Treatment in Pulmonary Arterial Hypertension 424 TORREY Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension (PAH): Circulating Biomarkers of Proliferation, Inflammation, and Fibrosis Improve With Treatment 425 A Randomized Controlled Trial of Palliative Care to Improve Health Related Quality of Life in Pulmonary Arterial Hypertension

203 Establishing a Novel Model System to Study Aberrant Tracheal Epithelial-chondrocyte Development Ex Vivo 204 Mediators of Antenatal Inflammation Propagating Chronic Neonatal Lung Disease 205 The IL-33/ST2-axis Contributes to the Development of Bronchopulmonary Dysplasia-associated Pulmonary Hypertension 206 Type I Interferon Disrupts Airway Cell Differentiation in Trisomy 21 207 Activation of Cellular Stress and Degradation Pathways by ABCA3 Trafficking Mutants 208 Mesenchyme Derived Inflammation Recruits Macrophages and Alters Saccular Stage Lung Microvascular Development 209 Neonatal Hyperoxia Impairs Mitophagy, Leading to Increased Cytosolic mtDNA Release and cGAS-STING Pathway Activation in the Lung 210 The Potentially Bronchoconstricting Enzyme AKR1A1 Is Expressed in Preterm Human Infants at Risk for Bronchopulmonary Dysplasia 211 Role of Medical Complexity and Respiratory 213 Blood Sphingolipids as an Early Predictor of Bronchopulmonary Dysplasia 214 Do Clinical Definitions of Bronchopulmonary Dysplasia (BPD) Severity Correlate With Objective Measurements of Lung Function in Premature Infants? 215 Increased Forced Expiratory Flows in Former Preterm Infants Randomized to Two Extra Weeks of Continuous Positive Airway Pressure (CPAP) in the NICU 216 Comparison of Airway Resistance Measurements Obtained by the Single Breath Occlusion Technique Versus Forced Oscillometry in Stable Preterm and Term Infants 217 Obstructive Respiratory Disease Progresses With Time in Children With Bronchopulmonary Dysplasia Bacteria in Time to Chronic Ventilator Liberation Among Children With Bronchopulmonary Dysplasia 212 Postnatal Selenium Deficiency Disrupts Alveolarization and Exacerbates Hyperoxia-induced Lung Developmental Deficits in Newborn Mice

BASIC • CLINICAL • TRANSLATIONAL POSTER DISCUSSION SESSION

D106 CUTTING-EDGE SCIENCE ON

BRONCHOPULMONARY DYSPLASIA

11:00 a.m. - 1:00 p.m.

San Diego Convention Center Room 1A-B (Upper Level)

Poster Viewing

11:00-11:45

Discussion 11:45-1:00 201 Hedgehog Pathway Regulates Alveolar Type II Cells in Human Lung Development 202 Abnormal Tracheal Epithelial Differentiation in Patients With Evolving BPD: Linking Ex Vivo and In Vivo Systems

ATS 2024 • San Diego, CA